THERANOSTICS AND PRECISION MEDICINE SPECIAL FEATURE: REVIEW ARTICLE

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application

1CRISTINA MÜLLER, PhD, 2KATHARINA A DOMNANICH, 1CHRISTOPH A UMBRICH and 1,2NICHOLAS P VAN DER MEULEN

1Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland
2Laboratory of Radiochemistry, Paul Scherrer Institut, Villigen-PSI, Switzerland

Address correspondence to: Dr Cristina Müller
E-mail: cristina.muller@psi.ch

ABSTRACT
Currently, different radiometals are in use for imaging and therapy in nuclear medicine: 68Ga and 111In are examples of nuclides for positron emission tomography (PET) and single photon emission computed tomography (SPECT), respectively, while 177Lu and 225Ac are used for β− and α-radionuclide therapy. The application of diagnostic and therapeutic radionuclides of the same element (radioisotopes) would utilize chemically-identical radiopharmaceuticals for imaging and subsequent treatment, thereby enabling the radiotheranostic concept. There are two elements which are of particular interest in this regard: Scandium and Terbium. Scandium presents three radioisotopes for theranostic application. 43Sc (T1/2 = 3.9 h) and 44Sc (T1/2 = 4.0 h) can both be used for PET, while 47Sc (T1/2 = 3.35 d) is the therapeutic match—also suitable for SPECT. Currently, 44Sc is most advanced in terms of production, as well as with pre-clinical investigations, and has already been employed in proof-of-concept studies in patients. Even though the production of 43Sc may be more challenging, it would be advantageous due to the absence of high-energetic γ-ray emission. The development of 47Sc is still in its infancy, however, its therapeutic potential has been demonstrated preclinically. Terbium is unique in that it represents four medically-interesting radioisotopes. 152Tb (T1/2 = 5.32 d) and 155Tb (T1/2 = 17.5 h) can be used for SPECT and PET, respectively. Both radioisotopes were produced and tested preclinically. 152Tb has been the first Tb isotope that was tested (as 152Tb-DOTATOC) in a patient. Both radionuclides may be of interest for dosimetry purposes prior to the application of radiolanthanide therapy. The decay properties of 161Tb (T1/2 = 6.89 d) are similar to 177Lu, but the coemission of Auger electrons make it attractive for a combined β−/Auger electron therapy, which was shown to be effective in preclinical experiments. 149Tb (T1/2 = 4.1 h) has been proposed for targeted α-therapy with the possibility of PET imaging. In terms of production, 161Tb and 155Tb are most promising to be made available at the large quantities suitable for future clinical translation. This review article is dedicated to the production routes, the methods of separating the radioisotopes from the target material, preclinical investigations and clinical proof-of-concept studies of Sc and Tb radionuclides. The availability, challenges of production and first (pre)clinical application, as well as the potential of these novel radionuclides for future application in nuclear medicine, are discussed.

INTRODUCTION
In nuclear medicine, the term “theranostics” refers to the application of radiopharmaceuticals for diagnosis and therapy.1 Radionuclides emitting γ-radiation or positrons can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET), respectively. The visualization of accumulated radioactivity and its quantification for dosimetry can provide important information towards the application of radionuclide therapy using the same targeting agent. The basic principle of radiotheranostics when using radioisotopes of the same element was applied more than 70 years ago in thyroid cancer patients.2 This idea was conceptualized by Dr S. Hertz and realized by treating the first patient with radioiodine in 1941.3,4 For several decades, radioiodine has been employed in clinical routine,5 however, the use of radiometals towards the same principle has been more challenging. Currently, somatostatin analogs are used in
Scandium and terbium are not only related in that they present several medically-interesting radioisotopes, but they also have similar chemical properties, allowing the coordination of the same chelator and, hence, the same targeting agent.

Herein, we report on the production routes and separation methods of Sc and Tb radioisotopes and summarize the application of the respective radioisotopes in preclinical settings. The first clinical proof-of-concept studies using Sc and Tb radioisotopes are also presented. The availability, challenges of production and the potential of these novel radioisotopes for future application in nuclear medicine are discussed.

**PRODUCTION OF SCANDIUM AND TERBIUM RADIOUN nuclides**

Production of scandium radioisotopes $^{44}\text{Sc}$

The production of $^{44}\text{Sc}$ was initially proposed by the development of a $^{44}\text{Ti}/^{44}\text{Sc}$ generator. The first such generator allowed elution of $185 \text{ MBq}^{44}\text{Sc}$ in a volume of 20 mL. A 10-min post-processing step of the $^{44}\text{Sc}$ eluate was established to reduce the volume and hydrochloric acid concentration, as well as to remove oxalate anions. $^{44}\text{Sc}$ obtained via this production route was applied for the labeling of DOTATOC, allowing its application in a patient for the first time. Recently, generator-produced $^{44}\text{Sc}$ was also used for the preparation of $^{44}\text{Sc}$-PSMA-617 and injected into prostate cancer patients.

Alternatively, the production of $^{44}\text{Sc}$ was proposed using natural calcium at a cyclotron. Activities of up to 650 MBq $^{44}\text{Sc}$ were

| Isotope | Half-life | $\beta^+$ $E_{\text{average}}$ [keV] (I) | $x$ and $\gamma$ with I > 10% $E$ [keV] (I) | $\beta^-$ $E_{\text{average}}$ [keV] (I) | Conv. & Auger electrons (>1 keV) $E_{\text{average}}$ [keV] (I) | $\alpha$ $E$ [keV] (I) |
|---------|-----------|-----------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------|
| $^{44}\text{Sc}$ | 3.9 h | 476 (88%)                          | 372 (23%)                      |                                 |                                 |                          |
| $^{47}\text{Sc}$ | 4.0 h | 632 (94%)                          | 1157 (100%)                    |                                 |                                 |                          |
| $^{149}\text{ Tb}$ | 3.35 d | –                                 | 159 (68%)                      | 162 (100%)                      |                                 |                          |
| $^{155}\text{ Tb}$ | 4.1 h | 730 (7%)                           | 42–50 (69%), 165 (26%), 352 (29%), etc. |                                 | 32 (85%) | 3967 (17%) |
| $^{159}\text{ Tb}$ | 17.5 h | 1140 (20%)                         | 42–50 (65%), 344 (64%)         |                                 | 36 (69%) |                          |
| $^{161}\text{ Tb}$ | 5.32 d | 45–53 (39%), 75 (10%)              |                                 | 154 (100%)                      | 19 (204%) |                          |

Table 1. Relevant decay characteristics of Sc and Tb isotopes
obtained after irradiation of the Ca target for 1 h, however, 44mSc, 43Sc and 46Sc were present in the final product as radioisotopic impurities. This may not be of concern for preclinical research, however, due to the long half-lives of these radioisotopes, it would be unfavorable for clinical application.27,28 Krajewski et al reported the production of 48Sc by irradiation of enriched 48Ca targets at a cyclotron and investigated optimal proton beam energies to obtain the best ratio between 48Sc and undesired 44mSc.29 At the Paul Scherrer Institut (PSI), Switzerland, the production of 46Sc from enriched 44Ca at a cyclotron was investigated in detail, resulting in the first preclinical application of a 46Sc-labeled biomolecule in tumor-bearing mice.10 The irradiation process as well as the separation method based on extraction chromatography was optimized to enable the production of quantities of up to ~2 GBq radionuclidically pure 44Sc when using proton beam energies of ~11 MeV.14 These developments resulted in the first application of cyclotron-produced 44Sc, in a clinical proof-of-concept study performed at Bad Berka, Germany.31

43Sc

The cyclotron production of 43Sc was proposed by proton irradiation of natural Ca targets for 1–2 h with α-particles, in an optimum energy range of 23.9–28.1 MeV to obtain activities for medical application.32–35 The 43Sc formation was induced via the nuclear reactions 40Ca(α, p)43Sc and 40Ca(α, n)43Ti→43Sc. The formed products were of high radionuclidic purity (>99%) and impurities were below 1.5*10−5 % of the 43Sc activity when irradiating enriched 40Ca targets. Another option for the production of 43Sc would be the irradiation of enriched 46Ca targets with deuterons using the 46Ca(d, n)43Sc nuclear reaction, however, no experimental data were acquired to date. A drawback of these production routes is the limited availability of cyclotrons with high-current α-beams, as well as cyclotrons providing deuterons beams.32,34

Recently, the production of 43Sc was investigated by comparing two different production routes based on proton irradiation of enriched 46Ti and 49Ca target material, respectively.15 The production via the 46Ti(p, α)43Sc nuclear reaction yielded a modest ~200 MBq 43Sc of high radionuclidic purity (>98%) at the end of a 7 h irradiation period when using 97% enriched 46Ti.15 The production via the 49Ca(p, n)43Sc nuclear reaction resulted in higher quantities of 43Sc, but the product consisted of a mixture of 43Sc and 44Sc at an activity ratio of 2:1, when using 57.9% enriched 49CaCO3.15 PET images of Derenzo phantoms were acquired with 43Sc obtained from irradiated 46Ca targets, as well as with 43Sc obtained via the 46Ti-based production route or as a mixture with 44Sc from 43Ca irradiations. In line with the smaller positron energy of 43Sc, the resolution was found to be the best for pure 43Sc [full width at half maximum (FWHM) = 1.87 ± 0.14 mm], followed by the 43Sc/44Sc mixture (FWHM = 2.04 ± 0.06) and 44Sc (FWHM = 2.12 ± 0.04) (Figure 1).36

47Sc

The production of 47Sc can be achieved via a number of different nuclear reactions using a cyclotron, reactor or electron linear accelerator. Misiak et al reported on the cyclotron production of 47Sc via the 46Ca(p, 2n)47Sc nuclear reaction.37 Using a proton energy range of 24–17 MeV would be optimal for this purpose, however, the radionuclidic purity using this route was determined to be only ~87%. Using enriched 46Ca for irradiation with 20 MeV protons may be a feasible route for the production of GBq activity levels of 47Sc, however, the high cost of enriched 46Ca has been prohibitive to investigate this production route to date.37 An alternative route investigated the α-particle irradiation of 44Ca targets at a cyclotron, inducing the 44Ca(α, p)47Sc nuclear reaction, but it provided a comparatively lower yield and radionuclidic purity.15

Domnanich et al investigated the production of 47Sc by irradiation of 46Ca targets in a high neutron flux reactor using the 46Ca(n, 2γ)47Sc nuclear reaction.38 The produced 47Ca decays to 47Sc with a half-life of 4.5 days, hence, presenting an elegant generator-like concept enabling multiple separations of in-grown 47Sc in an analogous process as described for the cyclotron-produced 44Sc.13 The same authors also reported on the irradiation of 45Ti at a reactor to obtain 47Sc via the 45Ti(n, p)47Sc nuclear reaction. This production route yielded low activities of 47Sc which was accompanied with a high percentage of co-produced 46Sc, however. Both characteristics are not desirable for radiopharmaceutical applications.13 Similar findings were reported elsewhere.39,40
The method of $^{47}$Sc production using electron linear accelerators (linacs) has also been proposed in the literature.\textsuperscript{31,42} Mamtimin et al studied the production of $^{47}$Sc via the $^{48}$Ti($\gamma$,p)$^{47}$Sc nuclear reaction by Monte Carlo simulations,\textsuperscript{42} while Yagi et al and Rotsch et al reported preliminary experimental results obtained with enriched $^{48}$Ti.\textsuperscript{43,44} Irradiation of natural Ti targets would result in many different Sc radioisotopes and, thus, low specific activity of $^{47}$Sc. Employing enriched $^{48}$Ti targets when irradiating with 22 MeV beam would maximize the $^{47}$Sc production and, simultaneously, minimize the formation of other unwanted Sc radionuclides.\textsuperscript{45} Another option, reported by Starovoitova et al and Rane et al, was to use an electron linac to produce $^{47}$Sc via the $^{48}$Ca($\gamma$,n)$^{47}$Ca$\rightarrow^{47}$Sc nuclear reaction.\textsuperscript{41,45}

Production of terbium radioisotopes

Based on calculations of excitation functions for light and heavy ion-induced reactions, Beyer et al suggested the $^{152}$Gd(p,4n)$^{149}$Tb nuclear reaction as a promising route for the $^{149}$Tb production.\textsuperscript{21} Irradiation of even highly-enriched $^{152}$Gd targets (which are not currently available) would presumably result in a mixture of various Tb radioisotopes, however.\textsuperscript{17} Alternatively, $^{149}$Tb could be produced via the indirect $^{152}$Nd(12C,5n)$^{149}$Dy$\rightarrow^{149}$Tb or directly via the $^{141}$Pr(12C,4n)$^{149}$Tb nuclear reaction, but with only limited production yields and radionuclidic purity.\textsuperscript{41,45} In initial experiments at the heavy ion cyclotron in Dubna, Russia, $^{149}$Tb was produced by irradiation of a $^{180}$Nd$_2$O$_3$ target for 1.25 h utilizing the indirect route to obtain a moderate yield of 2.7 MBq $^{149}$Tb.\textsuperscript{21} The production of $^{152}$Tb at a cyclotron via the $^{152}$Gd(p,n)$^{152}$Tb nuclear reaction would be problematic as well, because of the lack of highly-enriched target material and the formation of radioisotopic impurities. Proton irradiation of enriched $^{155}$Gd via the $^{155}$Gd(p,n)$^{155}$Tb reaction should be feasible to produce clinically-relevant quantities of $^{155}$Tb, however.\textsuperscript{46}

$^{149}$Tb, $^{152}$Tb and $^{155}$Tb were successfully produced by the high-energy proton irradiation of a tantalum foil target to induce spallation.\textsuperscript{17} The spallation products were released from the target and ionized. Mass separation of the isotopes, along with their isobars and pseudoisobars, was carried out using the online mass separator at ISOLDE/CERN, Switzerland, as previously reported,\textsuperscript{17} thereby, allowing the collection of the desired radionuclides in zinc-coated gold foils.\textsuperscript{17,46} After dissolution of the zinc layer of the foil, the $^{149}$Tb, $^{152}$Tb or $^{155}$Tb were separated from the matrix and its isobar and pseudoisobar impurities, respectively, using cation exchange chromatography and $\alpha$-hydroxyisobutyric acid as eluent. This procedure provided the final product in $\alpha$-hydroxyisobutyric acid solution at pH 4.75 enabling direct radiolabeling of tumor-targeting ligands.\textsuperscript{17}

$^{161}$Tb

The production of $^{161}$Tb was proposed by Lehenberger et al using the $^{160}$Gd(n,$\gamma$)$^{161}$Gd$\rightarrow^{161}$Tb nuclear reaction, a similar concept to the production of no-carrier added $^{177}$Lu (Figure 2).\textsuperscript{19} Highly-enriched $^{160}$Gd targets were irradiated for 2–3 weeks at the spallation-induced neutron source at PSI or for 1 week at the high neutron flux nuclear reactor at Institut Laue-Langevin, France.\textsuperscript{17} The product was separated from the Gd target material using ion exchange chromatographic methods to ensure provision of the final product in a small volume of dilute hydrochloric acid, as is the case for the commercially available $^{177}$Lu.\textsuperscript{17,19}

**PRÉCLINICAL APPLICATIONS**

Scandium radioisotopes

In order to obtain stable conjugation of scandium radioisotopes with tumor-targeting agents, the topic of chelation had to be addressed. Various open-chain polyanimo-polycarboxylate ligands and macrocycles were investigated for their suitability to coordinate Sc.\textsuperscript{16,49} It was determined that open-chain chelators formed complexes with Sc much faster than DOTA.\textsuperscript{49} On the other hand, DOTA bound Sc nuclides more efficiently, as compared to 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7-triazacyclodecane-1,4,7-triacetic acid (10-ane).\textsuperscript{16} DOTA chelators with one methylphosphonic/phosphinic acid pendant arm (DO3AP, DO3AP PrA and D3AP ABn) were investigated as alternative chelators.\textsuperscript{50} Another possibility for the coordination of Sc could be to use the 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine (AAZTA) chelator, allowing radiolabeling under mild conditions (room temperature).\textsuperscript{51} Chakravatry et al labeled...
a CHX-A-DTPA-functionalized antibody Fab fragment at room temperature within 45 min, resulting in >60% yield at an appreciable specific activity.\textsuperscript{52} CHX-A-DTPA is known to form more stable complexes than DTPA chelators and, hence, demonstrated stable coordination of \textsuperscript{44}Sc in mouse serum over 6 h at 37°C.\textsuperscript{52}

\textsuperscript{44}Sc

\textsuperscript{44}Sc was used for the radiolabeling of a variety of ligands, including somatostatin analogs,\textsuperscript{53–55} a bombesin analog,\textsuperscript{56} RGD peptides,\textsuperscript{57} folate derivatives\textsuperscript{58} and PSMA ligands.\textsuperscript{59} Pre-clinical experiments, including PET imaging, were performed in mice bearing tumors that express the target of interest. Eigner et al reported on the use of generator-produced \textsuperscript{44}Sc, in combination with a DOTA-derivatized purumycin.\textsuperscript{59} It allowed the visualization of Walker carcinoma 256 (rat breast carcinoma) and AT1 carcinoma (subline of Dunning R3327 rat prostate carcinoma) tumors via PET imaging in rats due to protein synthesis-specific accumulation of \textsuperscript{44}Sc-DOTA-puroycin.\textsuperscript{59} Among the first pre-clinical experiments performed with cyclotron-produced \textsuperscript{44}Sc was the study reported by Müller et al, where \textsuperscript{44}Sc-folate was investigated in \textit{vitro} using KB cells (human cervical cancer cells) as well as in KB tumor-bearing mice.\textsuperscript{50} In this study, it was also shown that the tissue distribution profile of \textsuperscript{44}Sc-folate was equal to that of \textsuperscript{177}Lu-folate. The authors concluded that \textsuperscript{44}Sc could serve for dosimetry purposes prior to \textsuperscript{177}Lu-based radionuclide therapy in a clinical setting.\textsuperscript{50} A similar pre-clinical setting was employed by the same authors using PSMA-617 for labeling with \textsuperscript{44}Sc, \textsuperscript{177}Lu and \textsuperscript{68}Ga to compare the radionuclides' influence on the overall \textit{in vitro} and \textit{in vivo} behavior.\textsuperscript{58} It was found that \textsuperscript{44}Sc-PSMA-617 most closely resembled the \textsuperscript{177}Lu-labeled version, showing almost identical \textit{in vitro} properties and biodistribution data and, hence, representing the concept of radiotheranostics. Domnach et al demonstrated that a DOTA chelator is more suitable for \textsuperscript{44}Sc complexation compared to NODAGA by using two pairs of peptides, DOTA/NODAGA-RGD and DOTA/NODAGA-NOC, respectively.\textsuperscript{55} In this regard, the behavior of \textsuperscript{44}Sc was opposite to that of \textsuperscript{68}Ga, which exhibited an increased stability when using NODAGA-functionalized peptides.\textsuperscript{55} While labeling of small molecules and peptides with \textsuperscript{44}Sc was exemplified many times, only few studies were reported about the \textsuperscript{44}Sc-labeling of proteins. Among those was the application of \textsuperscript{44}Sc for the labeling of a CHX-A-DTPA-functionalized Fab fragment of Cetuximab, a chimeric human-murine IgG1 monoclonal antibody that binds specifically to the epidermal growth factor receptor.\textsuperscript{52} Serial PET scans over a 6 h period revealed rapid and epidermal growth factor receptor-specific accumulation in U87MG tumors (human glioblastoma cell line) in a xenograft mouse model. Renal clearance was prominent, resulting in extensive accumulation of activity in the kidneys, whereas excretion via the hepatobiliary route was also observed.\textsuperscript{35} Based on these promising results, the development of new \textsuperscript{44}Sc-based radiopharmaceuticals for immunoPET imaging was encouraged by the authors.\textsuperscript{52} Another study investigated \textsuperscript{44}Sc in combination with an anti-HER2 affibody molecule (DOTA-Z\textsubscript{HER2}289).\textsuperscript{60} Affibody molecules are small scaffold proteins (58 amino acids, 7 kDa), known to refold after denaturation at elevated temperatures, hence, labeling at 95°C was possible.\textsuperscript{51} The \textsuperscript{44}Sc-DOTA-Z\textsubscript{HER2}289 was investigated \textit{in vitro} and \textit{in vivo}, using HER2-positive SKOV-3.ip tumor cells (human ovarian cancer cells) and in mouse SKOV-3.ip xenograft models. HER2-specific tumor uptake was demonstrated in biodistribution studies and increased tumor-to-background contrast was achieved at delayed time points (6 h after injection), due to the longer half-life of \textsuperscript{44}Sc as compared to \textsuperscript{68}Ga.\textsuperscript{60}

\textsuperscript{47}Sc

Radiolabeling of DOTA and DOTA-functionalized somatostatin receptor analogs (DOTATATE and DOTANOC) using \textsuperscript{44}Sc has been successfully demonstrated,\textsuperscript{15,32,35} however, pre-clinical studies using this radionuclide have not been published to date. In a recent study performed at PSI by the authors of this article, \textsuperscript{44}Sc was used for the labeling of PSMA-617. \textsuperscript{44}Sc-PSMA-617 was injected into a mouse bearing PC-3 PIP/Ilu tumors (PSMA-positive and PSMA-negative prostate cancer cells, respectively) for PET/CT imaging at different time points after injection (unpublished data), as was previously reported by Umbricht et al for \textsuperscript{43}Sc-PSMA-617.\textsuperscript{58} The same was also done with \textsuperscript{45}Sc and \textsuperscript{47}Sc-labeled PSMA-617 for PET and SPECT imaging, respectively. The obtained images of mice that received \textsuperscript{43}Sc-, \textsuperscript{44}Sc- and \textsuperscript{47}Sc-labeled PSMA-617 are shown in Figure 3. The \textit{in vitro} behavior of these chemically-identical radioligands is the same, independent of the Sc radioisotope employed. The result may be slightly improved in the case of \textsuperscript{43}Sc when compared to \textsuperscript{44}Sc; however, this was only visible in pre-clinical phantom studies. More importantly, there is the possibility of reducing the dose burden when using \textsuperscript{44}Sc, due to the absence of high-energy γ-radiation as emitted by \textsuperscript{44}Sc.

\textsuperscript{152}Tb

The concept of theranostic application (PET/β\textsuperscript{−}-therapy) with the matched pair of \textsuperscript{44}Sc/\textsuperscript{47}Sc radionuclides was proposed and exemplified in a preclinical study using a DOTA-folate conjugate.\textsuperscript{57} \textsuperscript{44}Sc-folate resulted in distinct visualization of FR-positive KB tumors using PET. The therapeutic potential of \textsuperscript{47}Sc-folate was successfully demonstrated by a delay in tumor growth and an increased survival time of treated mice, compared to an untreated control group.\textsuperscript{15}

Terbium radioisotopes

Preclinical application of all four terbium radioisotopes has been reported by Müller et al in 2012, when a proof-of-concept study was performed with a DOTA-folate conjugate in a folate receptor-positive tumor mouse model.\textsuperscript{37} This study demonstrated the feasibility of using \textsuperscript{152}Tb and \textsuperscript{159}Tb for PET and SPECT imaging, respectively, as well as the potential of using \textsuperscript{152}Tb and \textsuperscript{161}Tb for α- and β\textsuperscript{−}-Auger-electron therapy, respectively.

\textsuperscript{152}Tb

Due to an increased production yield achieved in recent years at ISOLDE/CERN, Switzerland, it was possible to investigate \textsuperscript{152}Tb in a more detailed study using a mouse model of somatostatin receptor-positive AR42J rat tumor xenografts (rat pancreatic cancer cells).\textsuperscript{62} DOTANOC, a clinically-established somatostatin analog, was labeled at variable specific activity and used for imaging purposes using a pre-clinical PET/CT scanner.\textsuperscript{62}
The tissue distribution profile of $^{152}$Tb-DOTANOC was equal to that of $^{177}$Lu-DOTANOC when applied to in the same animal model, showing favorable tumor-to-background ratios at higher specific activities. These results confirmed the assumption that the $^{152}$Tb-labeled compound would show the same in vivo behavior as its $^{177}$Lu-labeled match and could, therefore, be used for imaging and dosimetry prior to $^{177}$Lu-based radionuclide therapy. In this regard, and in view of the application in combination with longer-circulating radioligands and antibodies, the 17.5 h half-life of $^{152}$Tb would be considered an advantage.

$^{155}$Tb

The $\gamma$-ray energies of $^{155}$Tb make this radionuclide well suited for SPECT imaging (Table 1). Derenzo phantom studies performed with $^{155}$Tb showed an excellent spatial resolution compared to that obtained with the clinically-established SPECT nuclide $^{111}$In ($T_{1/2}=2.80$ d, $E_{\gamma}=171$ keV and 245 keV; Figure 4). SPECT/CT imaging was investigated using fast-clearing DOTA-peptides, including a minigastin-based peptide and DOTATATE, as well as longer-circulating biomolecules such as an albumin-binding DOTA-folate (cm09) and the L1-cell adhesion molecule (L1-CAM)-antibody chCE7. These biomolecules were labeled with $^{155}$Tb and used for preclinical imaging of tumor-bearing mice 4 h after injection of the radiolabeled peptides or 2 days and 3 days after injection of $^{155}$Tb-folate and $^{155}$Tb-chCE7, respectively. The images were of high quality, enabling visualization of even small lesions in the abdominal region, as well as in the liver of an intraperitoneal SKOV-3.ip tumor mouse model, days after injection of $^{155}$Tb-chCE7. $^{155}$Tb was proposed as an alternative option to $^{111}$In for dosimetry planning prior to the application of lanthanide-based radionuclide therapy.

$^{149}$Tb

The first pre-clinical application of $^{149}$Tb was reported by Beyer et al. A SCID mouse model of leukemia was used to demonstrate
the effect of $^{149}$Tb-labeled rituximab, a CD20-targeted antibody outfitted with CHX-A-DTPA chelators. Mice were administered with the radioimmunoconjugate (3.5 MBq, 5 µg per mouse) 2 days after intravenous injection of 5 million Daudi cells (human Burkitt lymphoma cells) before the appearance of manifested tumors. In 89% of the treated mice, the therapy resulted in tumor-free survival of more than 4 months, a significant increase in survival time as compared to the other groups.

Untreated animals developed signs of Burkitt lymphoma, which required euthanasia within 37 days. Animals treated with a low dose of unlabeled rituximab (5 µg per mouse) had to be euthanized within 43 days, while the treatment with a high dose of rituximab (300 µg per mouse) increased the lifetime, resulting in a median survival of 100 days. Preliminary dose estimation for humans reported by Beyer et al. revealed that a therapeutic activity of 5 GBq $^{149}$Tb-rituximab would result in a bone marrow radiation dose far below the critical level. $^{149}$Tb was also used for targeted radionuclide therapy using a DOTA-folate conjugate in a proof-of-concept study with KB tumor-bearing mice. At a later stage, the same model was used to investigate two different activity levels (2.2 MBq and 3.0 MBq per mouse, respectively) of $^{149}$Tb-folate. A dose-dependent effect was observed with regard to the tumor growth delay, as well as the median survival time which was increased to 30.5 day and 43 days, respectively, as compared to a median survival of 21 days in the case of untreated control animals. The therapeutic effect of $^{149}$Tb-folate was also confirmed in vitro, where the radiofolate reduced the tumor cell survival in a FR-specific manner. More recently, it was demonstrated for the first time in a pre-clinical setting that, based on the coemission of positrons, $^{149}$Tb can be used for PET imaging. An AR42J tumor-bearing mouse was injected with $^{149}$Tb-DOTANOC (7 MBq) followed by PET/CT imaging 2 h later. The high-quality images allowed distinct visualization of the tumor xenografts (Figure 5). The concept of $\alpha$-PET is entirely novel and would make $^{149}$Tb attractive for future clinical translation, potentially allowing the visualization of applied $^{149}$Tb-radioligands.

$^{161}$Tb

De Jong et al. reported on the first preclinical study performed with $^{161}$Tb in 1995 using $^{161}$Tb-octreotide to investigate the biodistribution in normal rats. It was found that $^{161}$Tb-octreotide cleared faster from the blood than $^{111}$In-octreotide, however, liver uptake was higher for the $^{161}$Tb-labeled version. The uptake in somatostatin receptor-positive tissues, such as CA20948 tumor (rat pancreatic cell line), pancreas and adrenals, was shown to be specific. Based on the results of this study, the authors concluded that $^{161}$Tb would be of interest for intraoperative imaging and radionuclide therapy. The first therapy study was reported in 2012, with a small number of KB tumor-bearing mice using a $^{161}$Tb-folate for a proof-of-concept investigation, where its potential for tumor growth inhibition was demonstrated (Figure 6).

The imaging potential using pre-clinical SPECT, as well as the therapeutic effect of $^{161}$Tb-folate, was investigated in a one-to-one comparison with $^{177}$Lu-folate and FR-positive KB and IGROV-1 tumor xenografts, respectively. In line with the increased mean absorbed tumor dose after administration of $^{161}$Tb-folate, it was more effective to treat KB tumors than $^{177}$Lu-folate applied at the same activity. As a consequence, the median survival time in $^{161}$Tb-folate treated mice was increased (54 days) as compared to mice treated with $^{177}$Lu-folate (35 day) or control mice (31 days) in the KB tumor models. The same held true for IGROV-1 tumor mice, even though the difference in tumor growth delay and survival time was less pronounced. Both radiofolates produced high-resolution pre-clinical images of the tissue...
Figure 6. Pre-clinical therapy study: the graph represents the tumor growth relative to the average tumor size (tumor volume) determined at Day 0, which was set to 1 (indicated as relative tumor size). The study was performed with five untreated mice (controls: green/blue) and five mice treated with 161Tb-folate (11 MBq/mouse; red/orange). In the treated group, four of the five mice showed complete tumor remission as shown by overlapping graphs. This research was originally published in JNM, Müller et al.17 PET, positron emission tomography; SPECT, single photon emission computed tomography.

Accumulation of radioactivity was found in multiple soft tissue and skeletal metastases, whereas physiological radioligand uptake was observed in the kidneys, liver, spleen, small intestine, urinary bladder and salivary glands. The kidneys received the highest absorbed radiation dose (0.354 mSv/MBq) after application of 44Sc-PSMA-617.26 The PET images obtained at 2 h after administration of 44Sc-PSMA-617 were compared to those obtained earlier using 68Ga-PSMA-11. Visual assessment of the PET scan acquired with 44Sc-PSMA-617 was at least of equal quality as the one obtained previously with 68Ga-PSMA-11 (Figure 7). Quantitative analysis revealed no differences between uptake of 44Sc-PSMA-617 and 68Ga-PSMA-11 in most organs, however, reduced accumulation of 44Sc-PSMA-617 was observed in the kidneys when compared to 68Ga-PSMA-11.26

Singh et al were the first to report on a proof-of-concept imaging study in patients using 44Sc produced at a cyclotron.31 Due to the high yield (~2 GBq) obtained from this production method, it was possible to ship 44Sc over a distance of 600 km from the production site at PSI, Switzerland, to Zentralklinik Bad Berka, Germany, requiring two half-lives’ travel time. At Bad Berka, 44Sc was used for the labeling of DOTATOC.31 Two male patients with well-differentiated, non-functional and functional neuroendocrine neoplasms, respectively, were selected for this study. After injection of 78 MBq and 96 MBq 44Sc-DOTATOC, eight sets of PET/CT scans were acquired at variable time points over a period of 24 h.31 Distinct uptake of radioactivity was observed in malignant lesions already at early time points, with best tumor-to-background at about 4 h after injection.

The tissue distribution was somewhat different when compared with that of 68Ga-DOTATOC (Figure 8), which may be attributed to the low specific activity of 44Sc-DOTATOC (~1.4 MBq/µg, >55 µg). The authors stated that decreasing the amount of injected peptide to <50 µg would be the aim for future studies in this regard. 44Sc-DOTATOC showed significant potential for PET/CT imaging and as a suitable diagnostic match to currently-used therapeutic radionuclides such as 177Lu and 90Y - as well as 44Sc, once it becomes commercially available.31

Terbium-152

The production of 152Tb at ISOLDE/CERN, followed by the chemical separation from catcher foils and impurities at PSI, resulted in a pure product in sufficient yields for use in a first-in-man application in 2016.31 152Tb was used for labeling of DOTATOC at Zentralklinik Bad Berka, and administered to a male patient with diagnosed metastatic, well-differentiated, functional neuroendocrine neoplasm of the terminal ileum.31 PET/CT scans were performed for restaging of the disease 8 years after the sixth cycle of peptide receptor radionuclide therapy. The scans were acquired over a period of 24 h after injection of 145 MBq 152Tb-DOTATOC.71 The resulting images allowed visualization of even small metastases, with increased tumor-to-background contrast at later time points (Figure 9). It was concluded that 152Tb would be of particular value for dosimetry prior to radionuclide therapy, due to its much longer half-life (17.5 h) enabling delayed PET scans, as compared to the very short half-life (68 min) of 68Ga which cannot serve this purpose.71

CLINICAL PROOF-OF-CONCEPT STUDIES

Scandium-44

The first clinical application of generator-produced 44Sc was performed in 2009.22 PET scans were acquired of a patient injected with 44Sc-DOTATOC, resulting in high-quality images up to 18 h after injection.22 More recently, 44Ti generator-produced 44Sc was employed for a first-in-man study of using 44Sc-PSMA-617.26 Four male patients with histologically-proven prostate carcinoma, who were scheduled for 177Lu-PSMA-617 therapy, were selected for the study. After the intravenous administration of 44Sc-PSMA-617 (50 ± 9.3 MBq), the patients underwent a dynamic PET scan of the abdomen over a period of 30 min, followed by static PET/CT scans from skull to midthigh up to 18 h after injection (Figure 7).26

The production of 152Tb at ISOLDE/CERN, followed by the chemical separation from catcher foils and impurities at PSI, resulted in a pure product in sufficient yields for use in a first-in-man application in 2016.31 152Tb was used for labeling of DOTATOC at Zentralklinik Bad Berka, and administered to a male patient with diagnosed metastatic, well-differentiated, functional neuroendocrine neoplasm of the terminal ileum.31 PET/CT scans were performed for restaging of the disease 8 years after the sixth cycle of peptide receptor radionuclide therapy. The scans were acquired over a period of 24 h after injection of 145 MBq 152Tb-DOTATOC.71 The resulting images allowed visualization of even small metastases, with increased tumor-to-background contrast at later time points (Figure 9). It was concluded that 152Tb would be of particular value for dosimetry prior to radionuclide therapy, due to its much longer half-life (17.5 h) enabling delayed PET scans, as compared to the very short half-life (68 min) of 68Ga which cannot serve this purpose.71
CONCLUSION

Based on the results of (pre)clinical studies, it is clear that $^{44}$Sc holds great promise for future applications as a novel PET nuclide for diagnostic imaging and for monitoring therapy in clinics. Whether $^{43}$Sc will replace $^{44}$Sc in future is unclear and critically dependent on the possibilities of producing it in large quantities and at reasonable cost. The investigation of $^{47}$Sc for therapy is still in its infancy and a potential utility for this novel $\beta^-$-particle-emitting radionuclide has to be defined.

Figure 7. MIP (top) and representative sections (bottom) of PET/CT examination of a patient suffering from mCRPC, with high tumor load, using (a) $^{44}$Sc-PSMA-617 (50 MBq, 60 min p.i.), and (b) $^{68}$Ga-PSMA-11 (120 MBq, 60 min p.i.). (c) On the right hand side, the planar scintigraphy is shown (top) and a representative section of the post-therapy SPECT/CT scan, about 24 h after application of 6.7 GBq $^{177}$Lu-PSMA-617. Figure adapted from Eppard et al. Theranostics 2017;7:4359–69.26 mCRPC, metastasized castration-resistant prostate cancer; MIP, maximum intensity projection; PET, positron emission tomography; PSMA, prostate-specific membrane antigen.

Figure 8. Comparison of serial images of the transverse section of liver, representing the lesion in segment VII (green arrow), obtained by PET/CT imaging of Patient 1 using somatostatin analogs for restaging after the third cycle of PRRT. (a) At 18 months after PRRT, the lesion was not detected on PET/CT image obtained with $^{68}$Ga-DOTATOC; (b) at 27 months after PRRT, the lesion was detected using $^{44}$Sc-DOTATOC; (c) a concurrent MRI performed within 24 h of the PET/CT scan obtained with $^{44}$Sc-DOTATOC co-registered the lesion seen on the PET/CT image; (d) at 36 months after PRRT, the lesion was detected on PET/CT images obtained with $^{68}$Ga-DOTATOC. Figure adapted from Singh et al.31 Cancer Biother Radiopharm 2017;32:124–32 [31] PET, positron emission tomography; PRRT, peptide receptor radionuclide therapy.
Among the Tb radionuclides, $^{161}\text{Tb}$ is undoubtedly the most advanced in terms of production and pre-clinical investigation. The similarity of $^{161}\text{Tb}$ to $^{177}\text{Lu}$ makes this novel radiolanthanide highly attractive for therapeutic application, potentially enabling a more effective therapy due to the coemission of Auger electrons while using the same targeting agents. $^{155}\text{Tb}$ could be produced at a cyclotron with potentially high yields; significant research efforts in this regard will be necessary, however. As a diagnostic match, $^{152}\text{Tb}$ may be of particular value for visualization and staging of malignancies and for dosimetry calculation prior to therapy with clinically employed and new radiolanthanides, such as $^{177}\text{Lu}$ and $^{161}\text{Tb}$, respectively.

The question on whether it would be beneficial or even essential, to use chemically identical radioligands for diagnosis and therapy is a controversial topic in the community and can only be addressed once the concept of “matched pair” radionuclides is realized in a clinical setting. Taking all relevant aspects into consideration, scandium provides the most promising diagnostic match whereas, in the case of terbium, the therapeutic radioisotopes are of most clinical interest. It is, therefore, possible and likely that $^{43/44}\text{Sc}$ could be used in tandem with $^{149/161}\text{Tb}$, since both elements can be stably coordinated with a DOTA chelator. This means that using the same tumor targeting agent for Sc/Tb-based radiotheranostics would be feasible.

Both scandium and terbium remain of utmost interest for further development, with regard to routine production in large quantities for future application in nuclear medicine. Basic research and more detailed (pre)clinical investigations will be required, to enable the specific aims of individual dose plans for personalized radionuclide therapy and the option of therapy monitoring, as well as therapy regimes tailored to their specific medical situation.
REFERENCES

1. Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, et al. Theranostics in nuclear medicine practice. Onco Targets Ther 2017; 10: 4821–8. doi: https://doi.org/10.2147/OTT.S140671

2. Ahn BC. Personalized medicine based on theranostic radiodiode molecular imaging for differentiated thyroid cancer. Biomed Res Int 2016; 2016: 1–9. doi: https://doi.org/10.1155/2016/1680484

3. Hertz S, Roberts A. Radioactive iodine as an indicator in thyroid physiology. V. The use of radioactive iodine in the differential diagnosis of two types of Graves’ disease. J Clin Invest 1942; 21: 31–2. doi: https://doi.org/10.1172/JCI12176

4. Hertz B, Schuller K, Saul Hertz M, Saul Hertz, MD (1905–1950): A pioneer in the use of radioactive iodine in the differential diagnosis of two types of Graves’ disease. J Nucl Med 2016; 57: 1155–5. doi: https://doi.org/10.2967/jnumed.2015.163677

5. Padma S, Sundaram PS. Radioiodine as an alternative to 177 Lu for targeted radioiodine molecular imaging for metastasized castrate-resistant prostate cancer. Theranostics in prostate cancer. J Nucl Med 2016; 55: 1658–64. doi: https://doi.org/10.2967/jnumed.114.141614

11. Kratochvil C, Bruchtexter F, Giesel FL, Weis M, Verbarg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiotherapy of metastatic castration-resistant prostate cancer. J Nucl Med 2016; 57: 1941–4. doi: https://doi.org/10.2967/jnumed.116.178673

12. Saltheke M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. [111]I-Bi-PSMA-617 targeted alpha-radioiodine therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 1099–100. doi: https://10.1007/s00259-017-3657-9

13. Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, et al. Promising prospects for [44 Sc]²⁴ Sc-based theranostics: application of [44 Sc] for radioiodine tumor therapy in mice. J Nucl Med 2014; 55: 1658–64. doi: https://doi.org/10.2967/jnumed.114.141614

14. van der Meulen NP, Bunka M, Domnanich KA, Müller C, Haller S, Vermeulen C, et al. Cyclotron production of [44 Sc]²⁴ Sc from bench to bedside. J Nucl Med Biol 2015; 42: 745–51. doi: https://doi.org/10.1016/j.jnmb.2015.05.005

15. Domnanich KA, Eichler R, Müller C, Jordi S, Yakusheva V, Braccini S, et al. Production and separation of [44 Sc] for radiopharmaceutical purposes. Clin Nucl Med 2010. 1701

16. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 2011; 105: 313–20. doi: https://doi.org/10.1016/j.jinorgbio.2011.03.003

17. Müller C, Zhermosekov K, Küster U, Johnston K, Dorrer H, Hohn A, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-radioiodine therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med 2012; 53: 1951–9. doi: https://doi.org/10.2967/jnumed.112.107540

18. Bernhardt P, Benjegård SA, Kölby L, Johansson K, Nilsson O, Ahlman H, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001; 51: 514–24. doi: https://doi.org/10.1016/S0360-3016(01)01663-7

19. Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grünberg J, Hohn A, et al. The low-energy β⁻ and electron emitter 161 Tb as an alternative to 186 Re for targeted radionuclide therapy. Nucl Med Biol 2011; 38: 917–24. doi: https://doi.org/10.1016/j.nucmedbio.2011.02.007

20. Champion C, Quinto MA, Morgat C, Zanotti-Fregonara P, Hindel E. Comparison between three promising β-emitting radioisotopes, [165 Cu]sc and [164 Tb], with emphasis on doses delivered to minimal residual disease. Theranostics 2016; 6: 1611–8. doi: https://doi.org/10.7150/thno.15132

21. Beyer GJ, Čomor JJ, Dakovic M, Solovier D, Tamburella C, Hagebo E, et al. Production routes of the alpha emitting 161 Tb for medical application. Radiochim Acta 2002; 90: 247–52. doi: https://doi.org/10.1524/ract.2002.90.5_2002.247

22. Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans 2011; 40: 6104–11. doi: https://doi.org/10.1039/c0dt01504k

23. Filosov DV, Loktionova NS, Rösch F. A [164 Tft][44 Sc]-based radionuclide generator for potential application of [44 Sc] based PET-radiopharmaceuticals. Radiochim Acta 2010; 98: 149. doi: https://doi.org/10.1524/ract.2010.1701

24. Pruszynski M, Loktionova NS, Filosov DV, Rösch F. Post-elution processing of [164 Ti][44 Sc] generator-derived [44 Sc] for clinical application. Appl Radiat Isot 2010; 68: 1636–41. doi: https://doi.org/10.1016/j.apradiso.2010.04.003

25. Roesch F. Scandium 44: benefits of a long-lived PET radionuclide available from the 44Ti/44Sc, generator system. Curr Radiopharm 2012; 5: 187–201. doi: https://doi.org/10.2174/1874471011205030187

26. Eppard E, de la Fuente A, Benezóva M, Khawar A, Bundschuh RA, Gärnter FC, et al. Clinical translation and first in-human use of [44 Sc]²⁴ Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer. Theranostics 2017; 7: 4359–69. doi: https://doi.org/10.7150/thno.20586

27. Severin GW, Engle JW, Valdovinos HV, Barnhart TE, Nickles RJ. Cyclotron produced [44 Sc] from natural calcium. Appl Radiat Isot 2012; 70: 1526–30. doi: https://doi.org/10.1016/j.apradiso.2012.04.030

28. Valdovinos HE, Hernandez R, Barnhart TE, Graves S, Cai W, Nickles RJ. Separation of cyclotron-produced [44 Sc] from a natural calcium target using a dipentyl pentylenephosphonate functionalized extraction resin. Applied Radiation and Isotopes 2015; 95: 23–9. doi: https://doi.org/10.1016/j.apradiso.2014.09.020
PSMA-11 and 68Ga-PSMA-617. *EJNMMI Res* 2017; 7: 9. doi: https://doi.org/10.1186/s13550-017-0257-4

59. Eigner S, Vera DR, Fellner M, Loktionova NS, Piel M, Lebeda O, et al. Imaging of protein synthesis: in vitro and in vivo evaluation of 44Sc-DOTA-puromycin. *Mol Imaging Biol* 2013; 15: 79–86. doi: https://doi.org/10.1007/s11307-012-0561-3

60. Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Karlström AE, et al. Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. *Nucl Med Biol* 2017; 45: 15–21. doi: https://doi.org/10.1016/j.nucmedbio.2016.10.004

61. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. *FEBS Lett* 2010; 584: 2670–80. doi: https://doi.org/10.1016/j.febslet.2010.04.014

62. Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, et al. Preclinical in vivo application of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. *Eur J Nucl Med Mol Imaging* 2014; 41: 1907–15. doi: https://doi.org/10.1007/s00259-014-2798-3

63. Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, et al. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice. *Nucl Med Biol* 2014; 41: e58–e65. doi: https://doi.org/10.1016/j.nucmedbio.2013.11.002

64. Beyer GJ, Miederer M, Vranjes-Durić S, Conor JJ, Küni G, Hartley O, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. *Eur J Nucl Med Mol Imaging* 2004; 31: 547–54. doi: https://doi.org/10.1007/s00259-003-1413-9

65. Müller C, Reber J, Haller S, Dorrer H, Köster U, Johnston K, et al. Folate receptor targeted alpha-therapy using terbium-149. *Pharmaceuticals* 2014; 7: 353–65. doi: https://doi.org/10.3390/ph7030353

66. Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. *EJNMMI Radiopharm Chem* 2017; 1: 5. doi: https://doi.org/10.1186/s41181-016-0008-2

67. de Jong M, Breezen WA, Bernard BF, Rolleman EJ, Hoiland LJ, Visser TJ, et al. Evaluation in vitro and in rats of 152Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. *Eur J Nucl Med Mol Imaging* 1995; 22: 608–16. doi: https://doi.org/10.1007/BF01254561

68. Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhermosekov K, et al. Direct in vivo and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. *Eur J Nucl Med Mol Imaging* 2014; 41: 476–85. doi: https://doi.org/10.1007/s00259-013-2563-z

69. Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, et al. Contribution of Auger/ conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. *EJNMMI Res* 2016; 6: 13. doi: https://doi.org/10.1186/s13550-016-0171-1

70. Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhermosekov K, Köster U, et al. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. *Eur J Nucl Med Mol Imaging* 2014; 41: 1907–15. doi: https://doi.org/10.1007/s00259-014-2798-3

71. Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, et al. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. *Dalton Trans* 2017; 46: 14638–46. doi: https://doi.org/10.1039/C7DT01936F